X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
peptides (317) 317
chemistry (315) 315
metallurgy (315) 315
organic chemistry (315) 315
human necessities (314) 314
hygiene (314) 314
medical or veterinary science (314) 314
preparations for medical, dental, or toilet purposes (314) 314
specific therapeutic activity of chemical compounds ormedicinal preparations (219) 219
beer (193) 193
microbiology (193) 193
biochemistry (192) 192
enzymology (192) 192
mutation or genetic engineering (192) 192
spirits (192) 192
vinegar (192) 192
wine (192) 192
compositions thereof (157) 157
culture media (157) 157
microorganisms or enzymes (157) 157
propagating, preserving or maintaining microorganisms (157) 157
agriculture (132) 132
animal husbandry (132) 132
care of birds, fishes, insects (132) 132
fishing (132) 132
forestry (132) 132
hunting (132) 132
new breeds of animals (132) 132
rearing or breeding animals, not otherwise provided for (132) 132
trapping (132) 132
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (104) 104
general tagging of cross-sectional technologies spanning over several sections of the ipc (86) 86
general tagging of new technological developments (86) 86
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (86) 86
technologies for adaptation to climate change (86) 86
technologies or applications for mitigation or adaptation againstclimate change (86) 86
testing (82) 82
investigating or analysing materials by determining theirchemical or physical properties (81) 81
measuring (81) 81
physics (81) 81
humans (57) 57
animals (41) 41
mice (35) 35
index medicus (34) 34
immunology (32) 32
oncology (27) 27
dendritic cells (25) 25
female (22) 22
immunotherapy (21) 21
article (18) 18
in-vivo (18) 18
cancer (17) 17
sugars (17) 17
derivatives thereof (16) 16
expression (16) 16
nucleic acids (16) 16
nucleosides (16) 16
nucleotides (16) 16
dendritic cells - immunology (15) 15
monoclonal-antibodies (15) 15
monoclonal antibodies (14) 14
antibodies, monoclonal - immunology (13) 13
compositions or test papers therefor (13) 13
condition-responsive control in microbiological orenzymological processes (13) 13
male (13) 13
measuring or testing processes involving enzymes, nucleicacids or microorganisms (13) 13
processes of preparing such compositions (13) 13
adult (12) 12
lectins, c-type - immunology (12) 12
mice, transgenic (12) 12
receptors, cell surface - immunology (12) 12
receptors, igg - immunology (12) 12
antigens, cd - immunology (11) 11
middle aged (11) 11
monoclonal-antibody (11) 11
antibodies, monoclonal - pharmacology (10) 10
antigens, neoplasm - immunology (10) 10
t cells (10) 10
antibodies (9) 9
cancer vaccines - immunology (9) 9
colony-stimulating factor (9) 9
immunity (9) 9
phagocytosis (9) 9
t-cells (9) 9
tumors (9) 9
antibodies, monoclonal - genetics (8) 8
antibodies, monoclonal - therapeutic use (8) 8
antigen presentation (8) 8
flow cytometry (8) 8
hematology (8) 8
mannose-binding lectins - immunology (8) 8
medicine, research & experimental (8) 8
responses (8) 8
t-lymphocytes - immunology (8) 8
transgenic mice (8) 8
vaccines (8) 8
aged (7) 7
antibody-dependent cell cytotoxicity (7) 7
antigen (7) 7
antigens (7) 7
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (445) 445
French (104) 104
German (49) 49
Chinese (13) 13
Spanish (9) 9
Portuguese (7) 7
Danish (5) 5
Korean (4) 4
Japanese (3) 3
Greek (2) 2
Russian (2) 2
Hungarian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 06/2015, Volume 522, Issue 7557, pp. 487 - 491
HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was largely ineffective in pre-clinical and clinical settings and was... 
THERAPY | VIRUS | HIV-1 NEUTRALIZATION | GENETIC-DETERMINANTS | IMMUNOTHERAPY | MULTIDISCIPLINARY SCIENCES | PASSIVE TRANSFER | IN-VIVO | VACCINE | MICE | MONOCLONAL-ANTIBODIES | Antibodies, Neutralizing - administration & dosage | Humans | Middle Aged | Viremia - therapy | Molecular Sequence Data | Antibodies, Monoclonal - therapeutic use | Male | Case-Control Studies | HIV Envelope Protein gp120 - immunology | Young Adult | HIV Infections - immunology | Antibodies, Neutralizing - immunology | HIV Antibodies - adverse effects | HIV Antibodies - immunology | Time Factors | HIV-1 - chemistry | Antibodies, Neutralizing - therapeutic use | Adult | Antibodies, Neutralizing - adverse effects | Female | HIV Antibodies - therapeutic use | HIV Envelope Protein gp120 - chemistry | HIV Antibodies - pharmacology | Binding Sites | Antibodies, Monoclonal - immunology | Amino Acid Sequence | Immunization, Passive - methods | HIV-1 - drug effects | HIV Infections - virology | Antibodies, Monoclonal - pharmacokinetics | Antibodies, Neutralizing - pharmacology | HIV Antibodies - administration & dosage | Viral Load - immunology | HIV-1 - immunology | Viremia - virology | Antibodies, Monoclonal - administration & dosage | HIV Infections - therapy | Viremia - immunology | Viral Load - drug effects | CD4 Antigens - metabolism | Evolution, Molecular | Viral antibodies | Virus diseases | Physiological aspects | Antibodies | HIV infection | Antigens | Immunoglobulins | Human immunodeficiency virus--HIV | Immunotherapy | Infections | Drug dosages | Binding sites | Immune system
Journal Article
Nature, ISSN 0028-0836, 07/2016, Volume 535, Issue 7613, pp. 556 - 560
Interruption of combination antiretroviral therapy in HIV-1-infected individuals leads to rapid viral rebound. Here we report the results of a phase IIa open... 
POTENT | REPLICATION | GENETIC-DETERMINANTS | BROADLY NEUTRALIZING ANTIBODIES | MULTIDISCIPLINARY SCIENCES | PASSIVE TRANSFER | SEQUENCE | CD4 BINDING | ANTIRETROVIRAL THERAPY | INFECTION | MONOCLONAL-ANTIBODIES | Anti-HIV Agents - pharmacology | Antibodies, Neutralizing - administration & dosage | Disease Reservoirs - virology | Humans | Middle Aged | Male | Proviruses - immunology | Anti-HIV Agents - administration & dosage | Tissue Distribution | Young Adult | HIV Infections - immunology | Proviruses - drug effects | Antibodies, Neutralizing - immunology | HIV-1 - growth & development | HIV Antibodies - immunology | HIV Envelope Protein gp160 - chemistry | Time Factors | Antibodies, Neutralizing - therapeutic use | Binding Sites - immunology | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Antibodies - therapeutic use | Historically Controlled Study | Binding Sites - drug effects | HIV Envelope Protein gp160 - metabolism | Drug Administration Schedule | HIV-1 - drug effects | HIV Infections - virology | HIV Antibodies - administration & dosage | Viral Load - immunology | Proviruses - growth & development | HIV-1 - immunology | HIV Envelope Protein gp160 - antagonists & inhibitors | Adolescent | HIV Infections - drug therapy | Aged | HIV Envelope Protein gp160 - immunology | Viral Load - drug effects | CD4 Antigens - metabolism | Prevention | Antiviral agents | HIV antibodies | Dosage and administration | Host-virus relationships | Drug therapy, Combination | Drug therapy | Health aspects | HIV infection | Methods | Clinical trials | Antiretroviral drugs | Immunoglobulins | Human immunodeficiency virus--HIV | Binding sites
Journal Article
Nature Medicine, ISSN 1078-8956, 02/2017, Volume 23, Issue 2, pp. 185 - 191
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 5032 - 5032
Introduction: gpNMB is an internalizable transmembrane protein overexpressed in 20 of breast cancers, 40 of triple-negative breast cancer (TNBC) and 80 of... 
Journal Article
by Weller, Michael and Butowski, Nicholas and Tran, David D and Recht, Lawrence and Recht, Lawrence D and Lim, Michael and Hirte, Hal and Ashby, Lynn and Mechtler, Laszlo and Goldlust, Samuel and Goldlust, Samuel A and Iwamoto, Fabio and Drappatz, Jan and O'Rourke, James and O'Rourke, Donald M and Wong, Mark and Hamilton, Mark G and Hamilton, Mark and Finocchiaro, Gaetano and Perry, James and Wick, Wolfgang and Green, Jennifer and He, Yi and Turner, Christopher D and Yellin, Michael J and Keler, Tibor and Davis, Thomas A and Stupp, Roger and Sampson, John H and Campian, Jian and Becker, Kevin and Barnett, Gene and Nicholas, Garth and Desjardins, Annick and Benkers, Tara and Wagle, Naveed and Groves, Morris and Kesari, Santosh and Horvath, Zsolt and Merrell, Ryan and Curry, Richard and Schuster, David and Mrugala, Maciej and Jensen, Randy and Trusheim, John and Lesser, Glenn and Belanger, Karl and Sloan, Andrew and Purow, Benjamin and Fink, Karen and Raizer, Jeffrey and Schulder, Michael and Nair, Suresh and Peak, Scott and Brandes, Alba and Mohile, Nimish and Landolfi, Joseph and Olson, Jon and Jennens, Ross and DeSouza, Paul and Robinson, Bridget and Crittenden, Marka and Shih, Kent and Flowers, Alexandra and Ong, Shirley and Connelly, Jennifer and Hadjipanayis, Costas and Giglio, Pierre and Mott, Frank and Mathieu, David and Lessard, Nathalie and Sepulveda, Sanchez Juan and Lövey, József and Wheeler, Helen and Inglis, Po-Ling and Hardie, Claire and Bota, Daniela and Lesniak, Maciej and Portnow, Jana and Frankel, Bruce and Junck, Larry and Thompson, Reid and Berk, Lawrence and McGhie, John and Macdonald, David and Saran, Frank and Soffietti, Riccardo and Blumenthal, Deborah and André de, Sá Barreto Costa Marcos and Nowak, Anna and Singhal, Nimit and Hottinger, Andreas and Schmid, Andrea and Srkalovic, Gordan and Baskin, David and Fadul, Camilo and Nabors, Louis and LaRocca, Renato and Villano, John and Paleologos, Nina and ... and ACT IV Trial Investigators and ACT IV trial investigators
The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1373 - 1385
Rindopepimut (also known as CDX-110), a vaccine targeting the deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet... 
GLIOMAS | ONCOLOGY | RECURSIVE PARTITIONING ANALYSIS | GROWTH-FACTOR | RADIOTHERAPY | CANCER | PEPTIDE | ADJUVANT TEMOZOLOMIDE | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Brain Neoplasms - pathology | ErbB Receptors - genetics | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Dose-Response Relationship, Drug | Young Adult | Glioblastoma - genetics | Time Factors | Dacarbazine - analogs & derivatives | Adult | Female | Vaccines, Subunit - adverse effects | Brain Neoplasms - mortality | Dacarbazine - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cancer Vaccines - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Cancer Vaccines - adverse effects | Treatment Outcome | Brain Neoplasms - drug therapy | Disease-Free Survival | Internationality | Vaccines, Subunit - administration & dosage | Glioblastoma - pathology | Survival Analysis | Aged | Temozolomide | Glioblastoma - drug therapy | Glioblastoma - mortality | Antimitotic agents | Clinical trials | Care and treatment | Product development | Antineoplastic agents | Glioblastoma multiforme | Analysis
Journal Article
Immunity, ISSN 1074-7613, 12/2017, Volume 47, Issue 6, pp. 1037 - 1050.e6
Given the limited efficacy of clinical approaches that rely on generated dendritic cells (DCs), it is imperative to design strategies that harness specialized... 
Axl+ dendritic cells | interindividual variation | plasmacytoid dendritic cells | dendritic cells | antibody targeting | tissue specialization | human | CyTOF | C-type lectins | subsets | HETEROGENEITY | IMMUNITY | C-TYPE LECTIN | DISTINCT | SUBSETS | IMMUNOLOGY | EXPRESSION | LINEAGE | TRANSCRIPTION FACTOR E2-2 | CANCER VACCINES | ANTIGEN | Antigens, CD - immunology | Skin - cytology | Spleen - immunology | Dendritic Cells - immunology | Humans | Receptor Protein-Tyrosine Kinases - immunology | Molecular Targeted Therapy | Antigens, CD - genetics | Palatine Tonsil - immunology | Palatine Tonsil - cytology | Neoplasms - therapy | Neoplasms - genetics | Immunotherapy | Proto-Oncogene Proteins - immunology | Female | Receptors, Immunologic - immunology | Antibodies, Monoclonal - chemistry | Skin - immunology | Gene Expression | Receptor Protein-Tyrosine Kinases - deficiency | Cancer Vaccines - administration & dosage | Cancer Vaccines - biosynthesis | Mice, Inbred C57BL | Biomarkers - analysis | Antibodies, Monoclonal - pharmacokinetics | Immunophenotyping | Proto-Oncogene Proteins - genetics | Spleen - cytology | Lymph Nodes - immunology | Proto-Oncogene Proteins - deficiency | Biological Variation, Individual | Lymph Nodes - cytology | Organ Specificity | Phenotype | Animals | Cytophotometry - methods | Receptor Protein-Tyrosine Kinases - genetics | Neoplasms - immunology | Antigens, Differentiation - genetics | Dendritic Cells - cytology | Mice | Antibodies, Monoclonal - metabolism | Neoplasms - pathology | Receptors, Immunologic - genetics | Antigens, Differentiation - immunology | Medical colleges | Microbiology | Dendritic cells | Analysis | Monoclonal antibodies | Skin | Immunity | Spleen | Drug delivery systems | Tonsil | Lymphoid tissue | Tissues | Blood | Cells | Axl protein | Genotype & phenotype | Tissue | Specialization | Receptors | Surface markers
Journal Article
Journal Article
中国免疫学杂志:英文版, ISSN 1672-7681, 2015, Volume 12, Issue 6, pp. 719 - 728
Previous studies have documented that selective delivery of protein antigens to cells expressing mannose receptor (MR) can lead to enhanced immune responses.... 
疫苗接种 | 甘露糖受体 | 癌症 | GM-CSF | 体液免疫反应 | 抗原呈递细胞 | 受体激动剂 | 人绒毛膜促性腺激素 | hCGβ | Toll-like receptor agonists | mannose receptor | HUMAN DENDRITIC CELLS | ANTIGEN PRESENTATION | IMMUNOLOGY | hCG beta | DEC-205 RECEPTOR | DC-SIGN | SUBSETS IN-VIVO | STEADY-STATE | MHC-I | EXPRESSION | CROSS-PRESENTATION | HIV GAG | Recombinant Fusion Proteins - immunology | Antigen-Presenting Cells - cytology | Humans | T-Lymphocytes - drug effects | Lymph Nodes - drug effects | Antibodies, Monoclonal - immunology | Polylysine - pharmacology | Th1 Cells - drug effects | Carboxymethylcellulose Sodium - analogs & derivatives | Poly I-C - pharmacology | Signal Transduction | Antigen-Presenting Cells - drug effects | Cancer Vaccines - administration & dosage | Toll-Like Receptors - immunology | Chorionic Gonadotropin, beta Subunit, Human - genetics | Mice, Transgenic | Lymph Nodes - immunology | Lymph Nodes - cytology | Receptors, Cell Surface - immunology | Mannose-Binding Lectins - immunology | Toll-Like Receptors - genetics | Recombinant Fusion Proteins - genetics | T-Lymphocytes - immunology | Mice | Th1 Cells - cytology | Oligodeoxyribonucleotides - pharmacology | Receptors, Cell Surface - genetics | Polylysine - analogs & derivatives | Lectins, C-Type - immunology | Lectins, C-Type - genetics | Th1 Cells - immunology | Cancer Vaccines - genetics | Immunity, Cellular - drug effects | Carboxymethylcellulose Sodium - pharmacology | Interferon-gamma - genetics | Recombinant Fusion Proteins - administration & dosage | Gene Expression Regulation | Chorionic Gonadotropin, beta Subunit, Human - immunology | Granulocyte-Macrophage Colony-Stimulating Factor - pharmacology | Antigen-Presenting Cells - immunology | Chorionic Gonadotropin, beta Subunit, Human - administration & dosage | Toll-Like Receptors - agonists | Antibodies, Monoclonal - genetics | Cancer Vaccines - immunology | Animals | Mannose-Binding Lectins - genetics | T-Lymphocytes - cytology | Antibodies, Monoclonal - administration & dosage | Interferon-gamma - immunology | Lymphocyte Count
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 4/2011, Volume 108, Issue 17, pp. 7131 - 7136
Journal Article